These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 8157196

  • 1. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
    Gadducci A, Ferdeghini M, Malagnino G, Prontera C, Fanucchi A, Annicchiarico C, Bianchi R, Fioretti P, Facchini V.
    Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
    [Abstract] [Full Text] [Related]

  • 2. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
    Sedlaczek P, Frydecka I, Gabryś M, Van Dalen A, Einarsson R, Harłozińska A.
    Cancer; 2002 Nov 01; 95(9):1886-93. PubMed ID: 12404282
    [Abstract] [Full Text] [Related]

  • 3. Serum soluble interleukin-2 receptor (sIL-2R) assay in cervical and endometrial cancer. Preliminary data.
    Ferdeghini M, Gadducci A, Prontera C, Marrai R, Malagnino G, Annicchiarico C, Fioretti P, Bianchi R.
    Anticancer Res; 1993 Nov 01; 13(3):709-13. PubMed ID: 8317901
    [Abstract] [Full Text] [Related]

  • 4. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors.
    Gebauer G, Rieger M, Jäger W, Lang N.
    Anticancer Res; 1999 Nov 01; 19(4A):2509-11. PubMed ID: 10470184
    [Abstract] [Full Text] [Related]

  • 5. Effects of granulocyte-macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumor necrosis factor-alpha in cancer patients.
    Crispino S, Lissoni P, Ardizzoia A, Rovelli F, Perego MS, Grassi MG, Barni S, Pittalis S, Tancini G.
    J Biol Regul Homeost Agents; 1993 Nov 01; 7(3):92-4. PubMed ID: 8135145
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma.
    Boyano MD, Garcia-Vázquez MD, López-Michelena T, Gardeazabal J, Bilbao J, Cañavate ML, Galdeano AG, Izu R, Díaz-Ramón L, Raton JA, Díaz-Pérez JL.
    Br J Cancer; 2000 Oct 01; 83(7):847-52. PubMed ID: 10970683
    [Abstract] [Full Text] [Related]

  • 11. Soluble interleukin-2 receptor in stage I-III melanoma.
    Ottaiano A, Leonardi E, Simeone E, Ascierto PA, Scala S, Calemma R, Bryce J, Caracò C, Satriano RA, Gianfranco N, Franco R, Botti G, Castello G.
    Cytokine; 2006 Feb 07; 33(3):150-5. PubMed ID: 16517174
    [Abstract] [Full Text] [Related]

  • 12. [Neopterin and a soluble interleukin-2 receptor in patients with systemic lupus erythematodes].
    Horák P, Hermanová Z, Ordeltová M, Faltýnek L, Kusá L, Budíková M, Vavrdová V, Opíchalová D, Ciferská H, Scudla V.
    Vnitr Lek; 2004 Jun 07; 50(6):422-7. PubMed ID: 15346634
    [Abstract] [Full Text] [Related]

  • 13. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
    Hurteau JA, Woolas RP, Jacobs IJ, Oram DC, Kurman CC, Rubin LA, Nelson DL, Berchuck A, Bast RC, Mills GB.
    Cancer; 1995 Nov 01; 76(9):1615-20. PubMed ID: 8635066
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
    Kang WD, Choi HS, Kim SM.
    Gynecol Oncol; 2010 Jan 01; 116(1):57-60. PubMed ID: 19818996
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Usefulness of the measurement of serum soluble IL-2 receptor alpha chain levels in clinical monitoring of non-Hodgkin lymphoma].
    Setoyama Y, Imai J, Ishikawa T, Sakaida H, Takaori-Kondo A, Kawamata S, Uchiyama T.
    Rinsho Byori; 1994 Aug 01; 42(8):834-42. PubMed ID: 7933620
    [Abstract] [Full Text] [Related]

  • 20. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD, Høgdall CK, Kjaer SK, Christensen L, Blaakaer J, Bock JE, Glud E, Høyer-Hansen G, Ring-Larsen H, Høgdall EV.
    Anticancer Res; 2004 Aug 01; 24(3b):1981-5. PubMed ID: 15274388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.